Endologix (ELGX) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Endologix Reports Results for the Fourth Quarter and Full Year 2015
February 22, 2016 4:05 PM ESTÂ Â Â 8% Constant Currency Revenue Growth for the Full Year 2015
2015 Nellix European Systems Increase 42% Over Prior Year
Provides 2016 Financial Guidance for Combined Company Following Completion of Merger with TriVascular Technologies, Inc. on February 3, 2016
IRVINE, Calif., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ: ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2015.
John McDermott, Endologix Chairman and Chief Executive Officer, said, We are entering 2016... More
Endologix to Participate in Two Investor Conferences in February
February 19, 2016 9:00 AM ESTIRVINE, Calif., Feb. 19, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to participate at two investor conferences in February. The first conference is the RBC Capital Markets 2016 Global Healthcare Conference in New York... More
